LLY

992.1

+1.45%↑

JNJ

243.48

-0.21%↓

ABBV

224.42

-1.08%↓

NVS

153.89

-0.26%↓

AZN

190.23

-0.59%↓

LLY

992.1

+1.45%↑

JNJ

243.48

-0.21%↓

ABBV

224.42

-1.08%↓

NVS

153.89

-0.26%↓

AZN

190.23

-0.59%↓

LLY

992.1

+1.45%↑

JNJ

243.48

-0.21%↓

ABBV

224.42

-1.08%↓

NVS

153.89

-0.26%↓

AZN

190.23

-0.59%↓

LLY

992.1

+1.45%↑

JNJ

243.48

-0.21%↓

ABBV

224.42

-1.08%↓

NVS

153.89

-0.26%↓

AZN

190.23

-0.59%↓

LLY

992.1

+1.45%↑

JNJ

243.48

-0.21%↓

ABBV

224.42

-1.08%↓

NVS

153.89

-0.26%↓

AZN

190.23

-0.59%↓

Search

Erasca Inc

Atidarymo kaina

14.82 -2.5

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

14.16

Max

15.4

Pagrindiniai rodikliai

By Trading Economics

Pajamos

3.3M

-31M

Darbuotojai

103

EBITDA

8.3M

-30M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

-6.84% downside

Dividendai

By Dow Jones

Kitas uždarbis

2026-03-18

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

4.2B

4.9B

Ankstesnė atidarymo kaina

17.32

Ankstesnė uždarymo kaina

14.82

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Erasca Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-12 23:12; UTC

Karštos akcijos

Stocks to Watch: Adobe, Mission Produce, Buzzfeed, Ulta

2026-03-12 22:15; UTC

Uždarbis

Wheaton Precious Metals Logs Higher 4Q Net Income, Boosts Dividend 18%

2026-03-12 21:42; UTC

Svarbiausios naujienos

Stryker Says Cyberattack Disruption Is Continuing

2026-03-12 21:29; UTC

Svarbiausios naujienos

Correction to War in Iran May Upend Brazil Central Bank's Plans Article

2026-03-12 21:27; UTC

Uždarbis

Adobe CEO to Depart as AI Boosts Sales -- Update

2026-03-12 20:46; UTC

Uždarbis

Adobe Posts Higher Sales With CEO Set to Depart

2026-03-12 20:21; UTC

Svarbiausios naujienos

Soybean Futures Higher on Instability in Iran --Daily Grain Highlights

2026-03-12 23:57; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Ongoing Middle East Conflict -- Market Talk

2026-03-12 23:38; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-12 23:38; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2026-03-12 22:13; UTC

Uždarbis

Orient Overseas: Tariff Measures, Trade Tensions Weighed on Results >0316.HK

2026-03-12 22:13; UTC

Uždarbis

Orient Overseas: Middle East Situation Have Added to Future Uncertainity >0316.HK

2026-03-12 22:13; UTC

Uždarbis

Orient Overseas: Charter Market Remains Exceptionally Tight With Vessels in Short Supply >0316.HK

2026-03-12 22:13; UTC

Uždarbis

Orient Overseas 2025 Rev $9.72B Vs. $10.70B >0316.HK

2026-03-12 22:13; UTC

Uždarbis

Orient Overseas 2025 Net $1.51B Vs. Net $2.58 >0316.HK

2026-03-12 22:13; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2026-03-12 22:13; UTC

Rinkos pokalbiai
Uždarbis

Adobe Says Customers Want to Try AI Products for Free First -- Market Talk

2026-03-12 21:16; UTC

Įsigijimai, susijungimai, perėmimai

Alexander & Baldwin: JV Formed by Affil of MW Group and Funds Affiliated With Blackstone and DivcoWest Completed Acquisition of All Outstanding A&B Common Shrs >ALEX

2026-03-12 21:04; UTC

Uždarbis

Adobe Earnings Beat Is Overshadowed by CEO Departure. The Stock Is Sliding. -- Barrons.com

2026-03-12 21:02; UTC

Uždarbis

Wheaton Precious Metals 4Q Adj EPS $1.22 >WPM

2026-03-12 21:02; UTC

Uždarbis

Wheaton Precious Metals 4Q Sales $865M >WPM

2026-03-12 21:02; UTC

Uždarbis

Wheaton Precious Metals 4Q Net $558.3M >WPM

2026-03-12 21:02; UTC

Uždarbis

Wheaton Precious Metals 4Q EPS $1.23 >WPM

2026-03-12 20:57; UTC

Rinkos pokalbiai
Svarbiausios naujienos

No Need For Canada Rate Increases Amid Jump in Bond Yields -- Market Talk

2026-03-12 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-03-12 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-03-12 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Eaton Completes Acquisition Of Leading Liquid-cooling Solutions Provider Boyd Thermal, Creating An Industry-leading Grid-to-chip Solution For Data Centers >ETN

2026-03-12 20:10; UTC

Uždarbis

Adobe Sees 2Q Rev $6.43B-$6.48B >ADBE

2026-03-12 20:05; UTC

Uždarbis

Adobe 1Q Rev $6.4B >ADBE

2026-03-12 20:05; UTC

Uždarbis

Adobe Sees 2Q Adj EPS $5.80-Adj EPS $5.85 >ADBE

Akcijų palyginimas

Kainos pokytis

Erasca Inc Prognozė

Kainos tikslas

By TipRanks

-6.84% į apačią

12 mėnesių prognozė

Vidutinis 14.44 USD  -6.84%

Aukščiausias 24 USD

Žemiausias 2 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Erasca Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

7

Pirkti

1

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

1.39 / 1.44Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

Very Strong Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
help-icon Live chat